Literature DB >> 18078355

Newborn screening for adrenoleukodystrophy: implications for therapy.

Gerald V Raymond1, Richard O Jones, Ann B Moser.   

Abstract

X-Linked adrenoleukodystrophy (X-ALD) is a progressive metabolic condition affecting the adrenal glands and nervous system of males. Although variable in the age of onset and presentation in families, X-ALD does present in characteristic phenotypes including a devastating childhood form that affects 35% of boys with this genetic condition. The majority of males with X-ALD will also develop adrenal insufficiency, which may result in crisis. Early detection is desirable in order to prevent morbidity from this condition. We have recently developed a tandem mass spectroscopy method that allows this to be done during newborn screening for other genetic disorder. In this review, we discuss the rationale for early detection, its effect on treatment, and some of the uncertainties.

Entities:  

Mesh:

Year:  2007        PMID: 18078355     DOI: 10.1007/BF03256261

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  16 in total

1.  Combined liquid chromatography-tandem mass spectrometry as an analytical method for high throughput screening for X-linked adrenoleukodystrophy and other peroxisomal disorders: preliminary findings.

Authors:  Walter C Hubbard; Ann B Moser; Silvia Tortorelli; Anita Liu; David Jones; Hugo Moser
Journal:  Mol Genet Metab       Date:  2006-07-07       Impact factor: 4.797

2.  Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening.

Authors:  Prachi Dubey; Gerald V Raymond; Ann B Moser; Sidharth Kharkar; Lena Bezman; Hugo W Moser
Journal:  J Pediatr       Date:  2005-04       Impact factor: 4.406

3.  Red blood cell ghosts are affected by adrenoleucodystrophy.

Authors:  G Arienti; E Carlini; S Laureti; P Brunetti; F Santeusanio
Journal:  Eur J Clin Invest       Date:  1996-10       Impact factor: 4.686

Review 4.  Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes.

Authors:  L Bezman; H W Moser
Journal:  Am J Med Genet       Date:  1998-04-13

5.  Diagnosis of adrenoleukodystrophy using dried blood spots.

Authors:  Y Ishikawa; R Minami; T Nakao
Journal:  Tohoku J Exp Med       Date:  1985-05       Impact factor: 1.848

6.  Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy.

Authors:  B M van Geel; L Bezman; D J Loes; H W Moser; G V Raymond
Journal:  Ann Neurol       Date:  2001-02       Impact factor: 10.422

Review 7.  Immunopathogenesis of adrenoleukodystrophy: current understanding.

Authors:  Michelle P Hudspeth; Gerald V Raymond
Journal:  J Neuroimmunol       Date:  2006-11-27       Impact factor: 3.478

8.  Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999.

Authors:  Charles Peters; Lawrence R Charnas; Ye Tan; Richard S Ziegler; Elsa G Shapiro; Todd DeFor; Satkiran S Grewal; Paul J Orchard; Susan L Abel; Anne I Goldman; Norma K C Ramsay; Kathryn E Dusenbery; Daniel J Loes; Lawrence A Lockman; Shunichi Kato; Patrick R Aubourg; Hugo W Moser; William Krivit
Journal:  Blood       Date:  2004-04-08       Impact factor: 22.113

9.  Attitudes toward presymptomatic testing and prenatal diagnosis for adrenoleukodystrophy among affected families.

Authors:  D Costakos; R K Abramson; J G Edwards; W B Rizzo; R G Best
Journal:  Am J Med Genet       Date:  1991-12-01

10.  Interactions of a very long chain fatty acid with model membranes and serum albumin. Implications for the pathogenesis of adrenoleukodystrophy.

Authors:  J K Ho; H Moser; Y Kishimoto; J A Hamilton
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

View more
  8 in total

Review 1.  Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and treatment guidelines.

Authors:  Nancy E Braverman; Gerald V Raymond; William B Rizzo; Ann B Moser; Mark E Wilkinson; Edwin M Stone; Steven J Steinberg; Michael F Wangler; Eric T Rush; Joseph G Hacia; Mousumi Bose
Journal:  Mol Genet Metab       Date:  2015-12-23       Impact factor: 4.797

2.  Antioxidant Capacity and Superoxide Dismutase Activity in Adrenoleukodystrophy.

Authors:  Bela R Turk; Benjamin E Theisen; Christina L Nemeth; Joel S Marx; Xiaohai Shi; Melissa Rosen; Richard O Jones; Ann B Moser; Paul A Watkins; Gerald V Raymond; Carol Tiffany; Ali Fatemi
Journal:  JAMA Neurol       Date:  2017-05-01       Impact factor: 18.302

Review 3.  Therapeutic strategies in adrenoleukodystrophy.

Authors:  Bela R Turk; Ann B Moser; Ali Fatemi
Journal:  Wien Med Wochenschr       Date:  2017-05-10

4.  Presymptomatic Lesion in Childhood Cerebral Adrenoleukodystrophy: Timing and Treatment.

Authors:  Eric James Mallack; Keith P Van Haren; Anna Torrey; Stephanie van de Stadt; Marc Engelen; Gerald V Raymond; Ali Fatemi; Florian S Eichler
Journal:  Neurology       Date:  2022-05-24       Impact factor: 11.800

5.  A report on state-wide implementation of newborn screening for X-linked Adrenoleukodystrophy.

Authors:  Katie Wiens; Susan A Berry; Hyoung Choi; Amy Gaviglio; Ashish Gupta; Amy Hietala; Daniel Kenney-Jung; Troy Lund; Weston Miller; Elizabeth I Pierpont; Gerald Raymond; Holly Winslow; Heather A Zierhut; Paul J Orchard
Journal:  Am J Med Genet A       Date:  2019-05-10       Impact factor: 2.802

Review 6.  X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies.

Authors:  Bela R Turk; Christiane Theda; Ali Fatemi; Ann B Moser
Journal:  Int J Dev Neurosci       Date:  2020-01-26       Impact factor: 2.457

7.  The gene expression profiles of induced pluripotent stem cells from individuals with childhood cerebral adrenoleukodystrophy are consistent with proposed mechanisms of pathogenesis.

Authors:  Xiao-Ming Wang; Wing Yan Yik; Peilin Zhang; Wange Lu; Patricia K Dranchak; Darryl Shibata; Steven J Steinberg; Joseph G Hacia
Journal:  Stem Cell Res Ther       Date:  2012-10-04       Impact factor: 6.832

8.  Peroxisome biogenesis disorders.

Authors:  Catherine Argyriou; Maria Daniela D'Agostino; Nancy Braverman
Journal:  Transl Sci Rare Dis       Date:  2016-11-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.